Antibodies to citrullinated proteins in rheumatoid arthritis

Japanese Journal of Clinical Immunology

Volumn 29, Issue 2, 2006, Pages 49-56

  Matsui, Toshihiro ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Anti cyclic citrullinated peptide antibody; Autoantibody; Citrullinated proteins; Rheumatoid arthritis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; CITRULLINE; CYCLOPEPTIDE; IMMUNOGLOBULIN M; RHEUMATOID FACTOR;

BLOOD; HUMAN; IMMUNOLOGY; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, ANTINUCLEAR; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CITRULLINE; HUMANS; IMMUNOGLOBULIN M; PEPTIDES, CYCLIC; PROGNOSIS; RHEUMATOID FACTOR;

EID: 33745180889     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.29.49     Document Type: Article

References (56)

1. Arnett FC., et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315–324, 1988.
2. Nienhuis RL., Mandema E.: A new serum factor in patients with rheumatoid arthritis; The antiperinuclear factor. Ann Rheum Dis. 23: 302–305, 1964.
3. Young BJ., et al.: Anti-keratin antibodies in rheumatoid arthritis. Br Med J. 14: 97–99, 1979.
4. Hassfeld W., et al.: Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum. 38: 777–785, 1995.
5. Menard HA., et al.: Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res. 2: 429–432, 2000.
6. Sebbag M., et al.: The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest. 95: 2672–2679, 1995.
7. Schellekens GA., et al.: Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 101: 273–281, 1998.
8. Schellekens GA., et al.: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 43: 155–163, 2000.
9. Goldbach-Mansky R., et al.: Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2: 236–243, 2000.
10. Bizzaro N., et al.: Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem. 47 (6): 1089–1093, 2001.
11. Bas S., et al.: Diagnostic tests for rheumatoid arthritis: Comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 41: 809–814, 2002.
12. Jansen AL., et al.: Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol. 29: 2074–2076, 2002.
13. Vasishta A.: Diagnosing early-onset rheumatoid arthritis: The role of anti-CCP antibodies. Am Clin Lab. 21: 34–36, 2002.
14. van Venrooij WJ., Hazes JM., Visser H.: Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med. 60: 383–388, 2002.
15. Lee DM., Schur PH.: Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis. 62: 870–874, 2003.
16. Suzuki K., et al.: High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol. 32: 197–204, 2003.
17. Pinheiro GC., et al.: Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med. 139: 234–235, 2003.
18. Araki, C., et al.: Usefulness of anti-cyclic citrullinated peptide antibodies (anti-CCP) for the diagnosis of rheumatoid arthritis. Rinsho Byori 52: 966–972, 2004.
19. Dubucquoi S., et al.: Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis. 63: 415–419, 2004.
20. Girelli F., et al.: Is anti cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis? Allerg Immunol (Paris). 36: 127–130, 2004.
21. Vallbracht I., et al.: Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis. 63: 1079–1084, 2004.
22. Nielen MM., et al.: Antibodies to citrullinated human ibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis. 64: 1199–204, 2005.
23. Brennan R., et al.: A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis; prospective cohort study. Br Med J. 313: 471–476, 1996.
24. Jansen LM., et al.: Predictors of functional status in patients with early rheumatoid arthritis. Ann Rheum Dis. 59: 223–226, 2000.
25. Yamanaka H., et al.: Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 43: 852–858, 2000.
26. Combe C., et al.: Prognostic factors for radiographic damage in early rheumatoid arthritis. Arthrits Rheum. 44: 1736–1743, 2001.
27. Drossaers-Bakker KW., et al.: Long-term outcome in rheumatoid arthritis: A simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year follow up. Arthritis Rheum. 47: 383–390, 2002.
28. Lindqvist EJ., et al.: Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis. 62: 611–616, 2003.
29. Sanmarti R., et al.: Radiological progression in early rheumatoid arthritis after DMARDs: A one-year follow-up study in a clinical setting. Rheumatology (Oxford), 42: 1044–1049, 2003.
30. Kroot EJ., et al.: The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-oncet rheumatoid arthritis. Arthritis Rheum. 43: 1831–1835, 2000.
31. Meyer O., et al.: Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis. 62: 120–126, 2003.
32. Forslind K., et al.: Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: Role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 63: 1090–1095, 2004.
33. Chen HA., et al.: The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis. 65: 35–39, 2006.
34. Alessandri C., et al.: Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis. 63: 1218–1221, 2004.
35. Caramaschi P., et al.: Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after inliximab treatment. Rheumatol Int. 26: 58–62, 2005.
36. van Boekel MA., et al.: Autoantibody systems in rheumatoid arthritis: Specificity, sensitivity and diagnostic value. Arthritis Res. 4: 87–93, 2002.
37. Masson-Bessiere C., et al.: In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol. 119: 544–552, 2000.
38. Reparon-Schuijt CC., et al.: Secretion of anticitrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum. 44: 41–47, 2000.
39. Masson-Bessiere C., et al.: The major synovial targets of the rheumatoid arthritis-specific antfilaggrin autoantibodies are deiminated forms of the alpha-and beta-chains of fibrin. J Immunol. 166: 4177–4184, 2001.
40. Vossenaar ER., et al.: Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther. 6: R142–R150, 2004.
41. Suzuki A., et al.: Anti-citrullinated collagen type I antibody is a target of autoimmunity in rheumatoid arthritis. Biochem Biophys Res Commun. 333: 418–426, 2005.
42. Burkhardt H., et al.: Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol. 35: 1643–1652, 2005.
43. Okazaki Y., et al.: Identification of citrullinated eukaryotic translation initiation factor 4G1 as novel autoantigen in rheumatoid arthritis. Biochem Biophys Res Commun. 341: 94–100, 2006.
44. Vossenaar ER., et al.: The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum. 50: 3485–3494, 2004.
45. Suzuki A., et al.: Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet. 34: 395–402, 2003.
46. Rantapaa-Dahlqvist S., et al.: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48: 2741–2749, 2003.
47. Nielen MM., et al.: Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum. 50: 380–386, 2004.
48. Matsui T., Shimada K., Tohma S.: Anti-cyclic citrullinated peptide antibody in rheumatic diseases other than rheumatoid arthritis. Clin Rheumatol. 2005 Nov 10: 1–2 [Epub ahead of print].
49. Aotsuka S., et al.: A retrospective study of the luctuation in serum levels of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. Clin Exp Rheumatol. 23: 475–481, 2005.
50. Alenius GM., Berglin E., Rantapaa-Dahlqvist S.: Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without manifestation of joint inflammation. Ann Rheum Dis. 2005 Aug 11; [Epub ahead of print].
51. Sauerland U. et al.: Clinical utility of the anti-CCP assay: Experiences with 700 patients. Ann N Y Acad Sci. 1050: 314–318, 2005.
52. Hoffman IE., et al.: Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis. 64: 330–332, 2005.
53. Gottenberg JE., et al.: Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren's syndrome. Ann Rheum Dis. 64: 114–117, 2005.
54. Cruyssen VB., et al.: Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis. 64: 1145–1149, 2005.
55. Bogliolo L., et al.: Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol. 32: 511–515, 2005.
56. Wener MH., et al.: Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum. 50: 2305–2308, 2004.